ZA201301013B - Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells - Google Patents

Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells

Info

Publication number
ZA201301013B
ZA201301013B ZA2013/01013A ZA201301013A ZA201301013B ZA 201301013 B ZA201301013 B ZA 201301013B ZA 2013/01013 A ZA2013/01013 A ZA 2013/01013A ZA 201301013 A ZA201301013 A ZA 201301013A ZA 201301013 B ZA201301013 B ZA 201301013B
Authority
ZA
South Africa
Prior art keywords
adjuvants
antigen
presenting cells
targeting
novel vaccine
Prior art date
Application number
ZA2013/01013A
Other languages
English (en)
Inventor
Anne-Laure Flamar
Gerard Zurawski
Jacques F Banchereau
Original Assignee
Baylor Res Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Institute filed Critical Baylor Res Institute
Publication of ZA201301013B publication Critical patent/ZA201301013B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA2013/01013A 2010-08-13 2013-02-06 Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells ZA201301013B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37376310P 2010-08-13 2010-08-13
PCT/US2011/047633 WO2012021834A1 (en) 2010-08-13 2011-08-12 Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells

Publications (1)

Publication Number Publication Date
ZA201301013B true ZA201301013B (en) 2015-10-28

Family

ID=45564978

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/01013A ZA201301013B (en) 2010-08-13 2013-02-06 Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells

Country Status (14)

Country Link
US (1) US20120039916A1 (cg-RX-API-DMAC7.html)
EP (1) EP2603235A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013535508A (cg-RX-API-DMAC7.html)
KR (1) KR20130108295A (cg-RX-API-DMAC7.html)
CN (1) CN103328005A (cg-RX-API-DMAC7.html)
AR (1) AR082686A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011289234B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013002940A2 (cg-RX-API-DMAC7.html)
CA (1) CA2807585A1 (cg-RX-API-DMAC7.html)
MX (1) MX2013001527A (cg-RX-API-DMAC7.html)
RU (1) RU2013110889A (cg-RX-API-DMAC7.html)
TW (1) TWI506035B (cg-RX-API-DMAC7.html)
WO (1) WO2012021834A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201301013B (cg-RX-API-DMAC7.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
ES2846400T3 (es) * 2007-05-03 2021-07-28 Agency For Science Tech And Research Astarstar Anticuerpos que se unen a un polipéptido PRL-1 o PRL-3 intracelular
WO2012122396A1 (en) * 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
AR088220A1 (es) 2011-08-29 2014-05-21 Baylor Res Inst Activacion de celulas dendriticas humanas por el receptor de dectina-1 o de tipo toll 2 (tlr2) en el control de la alergia y el asma
WO2013134293A1 (en) * 2012-03-05 2013-09-12 Duke University Vaccine formulation
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014031984A1 (en) * 2012-08-24 2014-02-27 Baylor Research Institute Immunological detection methods and compositions
US20160296609A1 (en) 2013-06-28 2016-10-13 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
CN103409451A (zh) * 2013-06-28 2013-11-27 扬州维克斯生物科技有限公司 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法
WO2015035173A1 (en) * 2013-09-05 2015-03-12 Duke University Nav1.7 antibodies and methods of using the same
EP3092256B1 (en) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Compounds and compositions for immunotherapy
US10286058B2 (en) 2014-01-13 2019-05-14 Baylor Research Institute Vaccines against HPV and HPV-related diseases
AU2015209277B2 (en) * 2014-01-22 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
AU2015258875B2 (en) 2014-05-16 2020-12-24 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
CN106456736A (zh) * 2014-06-02 2017-02-22 贝勒研究院 用于治疗过敏和炎性疾病的方法和组合物
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
JP6760919B2 (ja) 2014-07-09 2020-09-23 バーディー バイオファーマシューティカルズ インコーポレイテッド 腫瘍を治療するための抗ｐｄ−ｌ１組み合わせ
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN104689313A (zh) * 2015-03-04 2015-06-10 中国科学院海洋研究所 大菱鲆cd83分子作为疫苗佐剂的应用
US10624964B2 (en) 2015-05-01 2020-04-21 The Trustees Of The University Of Pennsylvania Methods and compositions for stimulating immune response using potent immunostimulatory RNA motifs
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CN116510015A (zh) * 2015-11-10 2023-08-01 耶鲁大学 用于治疗自身免疫疾病和癌症的组合物及方法
KR20180124014A (ko) 2015-12-15 2018-11-20 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) Ebv-세포 항원 및 표적화 모이어티를 포함하는 면역원성 컨스트럭트 및 그의 응용
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
AU2017228474C1 (en) 2016-03-04 2024-03-28 Abmuno Therapeutics Llc Antibodies to TIGIT
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
CA3049791A1 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
US11517567B2 (en) 2017-06-23 2022-12-06 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions
EP3645043A4 (en) * 2017-06-28 2021-04-07 The Board of Trustees of the Leland Stanford Junior University METHODS AND COMPOSITIONS FOR DECTIN 2 STIMULATION AND CANCER IMMUNOTHERAPY
CA3083231A1 (en) * 2017-11-29 2019-06-06 Adaptive Phage Therapeutics, Inc. Methods of vaccination using icosahedral phage
SG11202008291XA (en) * 2018-02-28 2020-09-29 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
JP7670614B2 (ja) * 2019-01-22 2025-04-30 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 抗原提示好中球由来樹状細胞およびその使用方法
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
KR20220004985A (ko) 2019-03-27 2022-01-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Cd40 활성화 특성을 가진 재조합 단백질
US20220298255A1 (en) * 2019-05-31 2022-09-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute E-cadherin activating antibodies and uses thereof
KR20220131895A (ko) * 2019-11-21 2022-09-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
JP2023525140A (ja) 2020-05-13 2023-06-14 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Ｏｘ４０活性化特性を有する組換えタンパク質
CA3184802A1 (en) 2020-05-26 2021-12-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
EP4157875A1 (en) 2020-06-02 2023-04-05 Arcus Biosciences, Inc. Antibodies to tigit
JP2023532304A (ja) 2020-07-01 2023-07-27 エーアールエス ファーマシューティカルズ オペレーションズ，インク． 抗ａｓｇｒ１抗体コンジュゲートおよびその使用
CN111850006B (zh) * 2020-07-27 2022-04-22 齐鲁工业大学 一种适用于低钙离子浓度的纤维小体对接蛋白组合突变体36865及应用
US20240010739A1 (en) 2020-11-12 2024-01-11 Institut National De La Santé Et De La Recherche Médicale (Inserm) Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
IL302874A (en) * 2020-11-18 2023-07-01 Pionyr Immunotherapeutics Inc Anti-Marco antibodies and their uses
KR20230124672A (ko) 2020-12-23 2023-08-25 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항원 제시 세포에 대한 momp vs4 항원의 표적화에 기반한클라미디아 백신
MX2023008986A (es) 2021-01-29 2023-08-15 Inst Nat Sante Rech Med Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna.
WO2023081806A2 (en) * 2021-11-04 2023-05-11 The General Hospital Corporation Anti-mesothelin antibody reagents
MX2024006003A (es) 2021-11-17 2024-08-06 Inst Nat Sante Rech Med Vacunas universales contra el sarbecovirus.
KR20250080855A (ko) 2022-10-05 2025-06-05 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 니파바이러스 감염에 대한 dc 표적 백신
EP4601682A1 (en) * 2022-10-13 2025-08-20 The Brigham & Women's Hospital, Inc. Methods and compositions for improving response to immunotherapy
KR102878250B1 (ko) * 2023-01-11 2025-10-31 서울대학교산학협력단 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물
WO2024216189A1 (en) * 2023-04-13 2024-10-17 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1057915C (zh) * 1994-09-19 2000-11-01 中国医学科学院医药生物技术研究所 免疫佐剂
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
WO2007103048A2 (en) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
EP2476432B1 (en) * 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
MX2009008140A (es) * 2007-02-02 2009-10-26 Baylor Res Inst Vacunas a base de antigeno dirigido a dcir expresado en celulas que presentan antigeno.
CA2717659C (en) * 2007-02-23 2017-08-22 Baylor Research Institute Therapeutic applications of activation of human antigen-presenting cells through dectin-1
DK2224954T3 (en) * 2007-11-07 2014-03-03 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
WO2010009346A2 (en) * 2008-07-16 2010-01-21 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
JP5883653B2 (ja) * 2009-03-10 2016-03-15 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗原提示細胞ターゲティング抗ウイルスワクチン
CN108373509A (zh) * 2009-03-10 2018-08-07 贝勒研究院 靶向抗原呈递细胞的抗病毒疫苗
CA2754862C (en) * 2009-03-10 2019-04-02 Baylor Research Institute Anti-cd40 antibodies and uses thereof
CA2798616A1 (en) * 2010-05-07 2011-11-10 Baylor Research Institute Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells

Also Published As

Publication number Publication date
BR112013002940A2 (pt) 2019-09-24
US20120039916A1 (en) 2012-02-16
RU2013110889A (ru) 2014-09-20
AU2011289234B2 (en) 2014-09-11
JP2013535508A (ja) 2013-09-12
AU2011289234A1 (en) 2013-02-21
EP2603235A4 (en) 2014-04-09
AR082686A1 (es) 2012-12-26
EP2603235A1 (en) 2013-06-19
CN103328005A (zh) 2013-09-25
WO2012021834A1 (en) 2012-02-16
MX2013001527A (es) 2013-04-24
TW201208696A (en) 2012-03-01
TWI506035B (zh) 2015-11-01
KR20130108295A (ko) 2013-10-02
CA2807585A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
ZA201301013B (en) Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
IL200088A0 (en) Vaccines based on targeting antigen to dcir expressed on antigen-presenting cells
IL223206A0 (en) Vaccine formulations
EP2429585A4 (en) VACCINE IMMUNOTHERAPY
GB201005005D0 (en) New vaccine
IL225667A0 (en) A new antigen
GB201007497D0 (en) Energy harvesting
IL222228A0 (en) Hiv vaccine
AU2012307348A8 (en) Vaccine
IL224022B (en) Thermally stable influenza vaccine
GB2476880B (en) Portable energy harvester
GB201014965D0 (en) Vaccine
SG10201808644PA (en) Recombinant mycobacterium as a vaccine
GB201003293D0 (en) Cancer vaccine
EP2543387A4 (en) MUCOSA VACCINE
GB201013006D0 (en) Vaccine
GB201006324D0 (en) Vaccine
ZA201302154B (en) Vaccine
IL219378A0 (en) Vertical axis solar powered generator
GB201001199D0 (en) Solar powered device
GB201009277D0 (en) Novel vaccine
GB201010054D0 (en) CTL vaccine
GB201012283D0 (en) Vaccine
GB201007589D0 (en) Vaccine
GB201007588D0 (en) Vaccine